BOSTON SCIENTIFIC BUYS LEADERSHIP POSITION IN INTERVENTIONAL NEURORADIOLOGY WITH $1.1 BIL. TARGET MERGER; STOCK DEAL RESOLVES COMPANIES' PATENT DISPUTE

Boston Scientific's $1.1 bil. merger agreement with Target Therapeutics puts the interventional neuroradiology segment firmly in the hands of large, diversified medical products firms.